Drug resistance is a major public health crisis thwarting the effective treatment and care of people living with tuberculosis (TB). But with the release of new curative medicines and patient-minded improvements of treatment guidelines, drug-resistant TB (DR-TB) no longer has to be a death sentence.
However, countries, policymakers and healthcare providers tasked with reaching and treating people living with DR-TB must take concrete actions to get lifesaving medicines to the people who need them most.
MSF Access Campaign’s DR-TB Drugs Under the Microscope report series examines the current landscape of DR-TB drug pricing and access policies and makes recommendations for governments, policymakers and healthcare providers to improve access to these lifesaving treatments. The eighth edition of the report was published in November 2022.